Whitepapers
Pharma white papers on contemporary issues, technologies, research, etc. are presented in this section to enable the readers with rich information and knowledge. This section provides white papers related to all the spheres of the pharma industry.
Roadmap to Biomarker Discovery: Innovations, Opportunities, and Breakthroughs
Biomarkers are indicators of homeostasis disease states or pharmacological interventions An ideal biomarker must be bina present or absent quantifiable in tissues cells body fluids or in simple physiological parameters
How Prancer RTSM® Enables Complex Studies - The Complex Study is Here to Stay
Clinical researchers are becoming much more creative in how they explore possible treatments They are leveraging more adaptive trials where phases can be combined or skipped based on positive results or where the protocol is amended to explore new treatments or disease states within the same trial
The Need For Adaptive Trial Design In Oncology Studies
Trial research needs to account for increased complexity and competition when recruiting patients in cancer studies Patients and oncologists have more choices than ever for the placement of qualified study participants Not only are treatments more specialised but the industry
Navigating IDMP Compliance in the Pharmaceutical Industry
In an era of increasing regulatory demands the pharmaceutical industry faces the challenge of adhering to the Identification of Medicinal Products IDMP standards This whitepaper provides guidance to understanding and implementing IDMP compliance outlining the benefits and potential challenges and offering practical solutions We at AdEx Partners as Trusted Leaders in Business Transformation off...
RNA Therapeutics
An exploration of a rapidly growing field in the biotech industry with the potential to revolutionise the treatment of a wide range of diseases
How Clinical Trial Complexity Impacts End Users
Traditionally complexity in clinical trials is translated into increased operational challenges due to the presence of several IMPs populations trial sites multiple sponsors andor manufacturers and contract research organizations CROs
Phase-Appropriate Analytical Method Development
Drug development requires an average overall investment of USD billion and remains at high risk due to the huge attrition rate phase after phase The preclinical development phase and the phase clinical trial show the highest attrition rate due to toxicity or drug metabolism pharmacokinetic issues Mitigating the risk during a new drug candidate development program starting from the discove...
The New Normal: How COVID-19 Became the Catalyst for Change
When COVID disrupted life sciences solutions were needed in realtime As the pandemic grew so did the need to innovate Workers met the challenges They completed tasks fulfilled inspections and remained vigilant in fulfilling regulatory requirements This paper presents findings from a roundtable hosted by PharmaLex
Driving value creation through medical affairs in China
After more than three decades of fast economic growth China has entered the new normal stage marked by a moderate and stable domestic GDP growth rate Healthcare has been elevated to a national level agenda by the current leadership with the releasing of China Health
Launching Global Clinical Trials—best Practices For Efficient And Cost-effective Translations: A Lionsbridge White Paper
Summary The target market for conducting global clinical trials has changed significantly moving beyond pharmaceutical early adopters to the mainstream marketplace This shift has placed a heightened focus on the language challenges and complexity of running a global clinical trial More and more companies are moving toward
